Compare Abeona Therapeutics Inc (ABEO) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Abeona Therapeutics Inc trades at $6.77 (market cap $373.32M), while YieldMax TSLA Option Income Strategy ETF trades at $26.87. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | TSLY | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Income / Options Overlay |
52-Week High | $7.23 | $48.25 |
52-Week Low | $4.17 | $26.16 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
TSLY trades at $28.45, up 6.04% with a bearish technical signal from moving averages. The ETF generates income through synthetic TSLA exposure and covered call strategies, currently yielding an annualized 52.65%. Recent weekly dividend announcements from YieldMax highlight the fund's income-focused strategy, though distributions are primarily return of capital.
The outlook remains cautious given technical bearishness and capped upside from covered call strategies. Key risks include TSLA volatility exposure and concentration in aggressive options strategies. Investors seeking high income may find value, but should monitor underlying TSLA performance and distribution sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
